Obeticholic Acid

<strong>Obeticholic Acid</strong>_x000D_ <strong>Catalog number:</strong> B2013707_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 25 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 420.6 g/mol_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> RT_x000D_ <strong>Keywords:</strong> (3α,5β, 6α,7α)-6-ethyl-3,7-dihydroxy-cholan-24-oic acid, 6-ECDCA, 6a-Ethyl-Chenodeoxycholic Acid, OCA_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Lancet. 2019 Dec 14;394(10215):2184-2196._x000D_ 2: Obeticholic Acid 2019 Dec 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–._x000D_ 3: Chapman RW, Lynch KD. Obeticholic acid-a new therapy in PBC and NASH Br Med Bull. 2020 May 15;133(1):95-104._x000D_ 4: Xiong X, Ren Y, Cui Y, Li R, Wang C, Zhang Y. Obeticholic_acid protects mice against lipopolysaccharide-induced liver injury and inflammation Biomed Pharmacother. 2017 Dec;96:1292-1298._x000D_ 5: Floreani A, Gabbia D, De Martin S. Obeticholic Acid for Primary Biliary Cholangitis Biomedicines. 2022 Oct 2;10(10):2464._x000D_ 6: Zhou J, Huang N, Guo Y, Cui S, Ge C, He Q, Pan X, Wang G, Wang H, Hao H. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis Acta Pharm Sin B. 2019 May;9(3):526-536._x000D_ 7: Krupa K, Hapshy V, Nguyen H, Parmar M. Obeticholic Acid 2023 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–._x000D_ 8: Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study J Hepatol. 2022 Mar;76(3):536-548._x000D_ 9: Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet. 2015 Mar 14;385(9972):956-65._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/27532829">10: Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis N Engl J Med. 2016 Aug 18;375(7):631-43. </a>_x000D_ _x000D_ <strong>Products Related to Obeticholic Acid can be found at</strong> <a href="https://moleculardepot.com/product-category/Chemicals/"> Chemicals</a>